Ribociclib is prescribed for:
- HR-positive, HER2-negative advanced breast cancer
- Pre/perimenopausal and postmenopausal women
- With endocrine therapy
- Oncology targeted treatment
Demonstrated overall survival benefit in clinical trials.
Back to Medication Guide
Ribociclib
Generic Name: Ribociclib
Brand Names: Kisqali
Ribociclib is a CDK4/6 inhibitor for advanced HR+/HER2- breast cancer with proven survival benefit.
OncologyCDK4/6 Inhibitor
What It's Used For
Side Effects
Common side effects:
- Neutropenia
- Nausea
- Fatigue
- Diarrhea
- Alopecia
Serious side effects:
- QT prolongation (requires ECG monitoring)
- Hepatotoxicity
- Severe neutropenia
Additional Information
What is Ribociclib?
Ribociclib is a CDK4/6 inhibitor with demonstrated overall survival improvement.
ECG Monitoring
Requires ECG monitoring due to QT prolongation risk - at baseline, day 14 of cycle 1, and as indicated.
Survival Benefit
One of few targeted therapies to show overall survival benefit in advanced breast cancer.
For more information, see MedlinePlus.
Medical Disclaimer: This information is for educational purposes only and should not be considered medical advice. Always consult with your healthcare provider before starting, stopping, or changing any medication. Your doctor can provide personalized recommendations based on your specific health condition and medical history.
Loading questions...
Ask Dr. Zimmer
Have questions about Ribociclib? Get expert answers from Dr. Zimmer.
Privacy: Your questions are posted anonymously for your health privacy. Your name and email are only used for admin purposes.
Questions are reviewed before posting. You'll see your question and Dr. Zimmer's answer below once approved.